SA523442866B1 - خلايا جذعية وسيطية تشارك في التعبير عن واستخداماتها cxcr4 وil-10 - Google Patents

خلايا جذعية وسيطية تشارك في التعبير عن واستخداماتها cxcr4 وil-10

Info

Publication number
SA523442866B1
SA523442866B1 SA523442866A SA523442866A SA523442866B1 SA 523442866 B1 SA523442866 B1 SA 523442866B1 SA 523442866 A SA523442866 A SA 523442866A SA 523442866 A SA523442866 A SA 523442866A SA 523442866 B1 SA523442866 B1 SA 523442866B1
Authority
SA
Saudi Arabia
Prior art keywords
cxcr4
stem cells
mesenchymal stem
utilization
expression
Prior art date
Application number
SA523442866A
Other languages
Arabic (ar)
English (en)
Inventor
رونسيرو، جوان أنطونيو بورين
أرانز ماريانو جارسوا–
داميان جارسوا-أولمو،
فيريرا، مارينا إنماكولادا جارين
جارسوا، ماريا فرنانديز
سانتالا، مرسيدس لوبيز
روساريو هيرفاس-سالكيدو،
رودريجيز، ميريام هيرناندو
جونزاليس، روزا ماريا يانيز
Original Assignee
كونسورسيو سنترو دي انفستجشن بيومديكا اين ريد
سنترو دي انفستجشنز انيرجيتكاس، ميديوامبينتالس واي تيكنولوجيز، او.ايه.، ام.بي.
فونداشن انستيتيوت دي انفستجشن سانتاريا فونداشن جيمينز دياز
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by كونسورسيو سنترو دي انفستجشن بيومديكا اين ريد, سنترو دي انفستجشنز انيرجيتكاس، ميديوامبينتالس واي تيكنولوجيز، او.ايه.، ام.بي., فونداشن انستيتيوت دي انفستجشن سانتاريا فونداشن جيمينز دياز filed Critical كونسورسيو سنترو دي انفستجشن بيومديكا اين ريد
Publication of SA523442866B1 publication Critical patent/SA523442866B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SA523442866A 2020-09-07 2023-03-07 خلايا جذعية وسيطية تشارك في التعبير عن واستخداماتها cxcr4 وil-10 SA523442866B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382792.8A EP3964265A1 (en) 2020-09-07 2020-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
PCT/EP2021/074612 WO2022049306A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Publications (1)

Publication Number Publication Date
SA523442866B1 true SA523442866B1 (ar) 2024-05-05

Family

ID=72473480

Family Applications (1)

Application Number Title Priority Date Filing Date
SA523442866A SA523442866B1 (ar) 2020-09-07 2023-03-07 خلايا جذعية وسيطية تشارك في التعبير عن واستخداماتها cxcr4 وil-10

Country Status (11)

Country Link
US (1) US20230398152A1 (enExample)
EP (2) EP3964265A1 (enExample)
JP (2) JP2023540599A (enExample)
KR (1) KR20230082622A (enExample)
CN (1) CN116507733A (enExample)
AU (1) AU2021337798A1 (enExample)
BR (1) BR112023004167A2 (enExample)
CA (1) CA3194344A1 (enExample)
MX (1) MX2023002741A (enExample)
SA (1) SA523442866B1 (enExample)
WO (1) WO2022049306A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN115927178A (zh) * 2022-11-17 2023-04-07 华夏源(上海)生物科技有限公司 一种检测间充质干细胞抑制b细胞分化为浆细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637856D1 (en) * 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
CA2566267A1 (en) * 2005-12-09 2007-06-09 University Health Network Thymidylate kinase mutants and uses thereof
CA2784861A1 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
EP3487991B1 (en) * 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
JP7493497B2 (ja) * 2018-06-19 2024-05-31 フォンダッツィオーネ・テレソン・エティエッセ 操作された樹状細胞の生産及びその使用

Also Published As

Publication number Publication date
CA3194344A1 (en) 2022-03-10
US20230398152A1 (en) 2023-12-14
MX2023002741A (es) 2023-05-26
JP2026082892A (ja) 2026-05-19
WO2022049306A1 (en) 2022-03-10
JP2023540599A (ja) 2023-09-25
KR20230082622A (ko) 2023-06-08
EP3964265A1 (en) 2022-03-09
AU2021337798A1 (en) 2023-05-18
EP4210834A1 (en) 2023-07-19
CN116507733A (zh) 2023-07-28
BR112023004167A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
MX2023002741A (es) Células madre mesenquimales que coexpresan cxcr4 e il -10 y usos de las mismas.
Casiraghi et al. Mesenchymal stromal cells to promote solid organ transplantation tolerance
Li et al. Interactions between mesenchymal stem cells and the immune system
Zheng et al. Mesenchymal stromal cells affect disease outcomes via macrophage polarization
Ansboro et al. Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both?
de Oliveira Bravo et al. Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression
Baron et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning
English et al. Mesenchymal stromal cells: facilitators of successful transplantation?
Uccelli et al. Mesenchymal stem cells in health and disease
Peltzer et al. Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges
CL2019003390A1 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
Stiner et al. Transplantation of stem cells from umbilical cord blood as therapy for type I diabetes
MY155137A (en) Compounds that expand hematopoietic stem cells
Cheng et al. The impact of mesenchymal stem cell source on proliferation, differentiation, immunomodulation and therapeutic efficacy
MX2019010385A (es) Dispositivos, metodos y composiciones utiles en la crio-conservacion, -almacenamiento, -transporte y aplicacion de celulas terapeuticas de mamiferos.
Mohanty et al. Immunomodulatory properties of bone marrow mesenchymal stem cells: Aparna Mohanty et al.
MX2024008571A (es) Células beta hipoinmunes diferenciadas de las células madre pluripotentes y usos y métodos relacionados.
RU2013141914A (ru) Лечение амиотрофического бокового склероза с использованием полученных из пуповины клеток
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
Jin et al. Next generation of neurological therapeutics: native and bioengineered extracellular vesicles derived from stem cells
Strom et al. Recently discovered T cell subsets cannot keep their commitments
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
Zhang et al. Combining acellular nerve allografts with brain-derived neurotrophic factor transfected bone marrow mesenchymal stem cells restores sciatic nerve injury better than either intervention alone
WO2025049959A3 (en) Gene editing systems, compositions, and methods for treatment of vexas syndrome
K. Sandberg et al. HIV-1 Vpu interference with innate cell-mediated immune mechanisms